IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd EBITDA Margin for the year ending December 31, 2023: -472.38%

IceCure Medical Ltd EBITDA Margin is -472.38% for the year ending December 31, 2023, a 11.63% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

IceCure Medical Ltd EBITDA Margin for the year ending December 31, 2022 was -534.55%, a -130.49% change year over year.
IceCure Medical Ltd EBITDA Margin for the year ending December 31, 2021 was -231.92%, a -132.24% change year over year.
IceCure Medical Ltd EBITDA Margin for the year ending December 31, 2020 was -99.86%, a 63.98% change year over year.
IceCure Medical Ltd EBITDA Margin for the year ending December 31, 2019 was -277.25%, a 13.16% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years